PDCD1 and melanoma: Our study aimed to investigate the immunotherapeutic potential of a novel next-generation TGF-β2 antisense oligonucleotide (ngTASO) in combination with anti-PD-1 therapy using a melanoma-bearing human immune system mouse model.